综述 |
|
|
|
|
纳米抗体在传染病的预防、诊断和治疗中的应用 * |
梅雅贤,王玥,罗文新() |
厦门大学公共卫生学院 国家传染病诊断试剂与疫苗工程技术研究中心 厦门 361102 |
|
Application of Nano-antibody in the Prevention, Diagnosis and Treatment of Infectious Diseases |
MEI Ya-xian,WANG Yue,LUO Wen-xin() |
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen 361102, China |
[1] |
Sanaei M, Setayesh N, Sepehrizadeh Z, et al. Nanobodies in human infections: prevention, detection, and treatment. Immunological Investigations, 2019: 1-22.
doi: 10.1080/08820139.2020.1817934
pmid: 32954867
|
[2] |
Statistics N B O. National data.[2020-06-03]. http://data.stats.gov.cn/search.htm?s=%E4%BC%A0%E6%9F%93%E7%97%85.
doi: 10.3390/data4010020
pmid: 30956970
|
[3] |
Worldmeter. Covid-19 coronavirus pandemic. [2020-06-03]. https://www.worldometers.info/coronavirus/.
|
[4] |
百度. 疫情实时大数据报告. [2020-06-03]. https://voice.baidu.com/act/newpneumonia/newpneumonia#tab4.
|
[5] |
Hey A. History and practice: Antibodies in infectious diseases. Microbiology Spectrum, 2015, 3(2): AID-0026-2014.
doi: 10.1128/microbiolspec.MDNA3-0058-2014
pmid: 26104699
|
[6] |
Steeland S, Vandenbroucke R E, Libert C. Nanobodies as therapeutics: Big opportunities for small antibodies. Drug Discovery Today, 2016,21(7):1076-1113.
doi: 10.1016/j.drudis.2016.04.003
pmid: 27080147
|
[7] |
Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, et al. Nanobodies and their potential applications. Nanomedicine, 2013,8(6):1013-1026.
doi: 10.2217/nnm.13.86
pmid: 23730699
|
[8] |
D’huyvetter M, Vincke C, Xavier C, et al. Targeted radionuclide therapy with a 177lu-labeled anti-her2 nanobody. Theranostics, 2014,4(7):708-720.
doi: 10.7150/thno.8156
pmid: 24883121
|
[9] |
Oliveira S, Van Dongen G a M S, Walsum M S-V, et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Molecular Imaging, 2012, 11(1): 7290.2011.00025.
pmid: 22418021
|
[10] |
Abulrob A, Sprong H, Van Bergen En Henegouwen P, et al. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. Journal of Neurochemistry, 2005,95(4):1201-1214.
doi: 10.1111/j.1471-4159.2005.03463.x
pmid: 16271053
|
[11] |
Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Frontiers in Immunology, 2017,8:1603-1603.
doi: 10.3389/fimmu.2017.01603
pmid: 29213270
|
[12] |
Muyldermans S, Baral T N, Retarnozzo V C, et al. Camelid immunoglobulins and nanobody technology. Veterinary Immunology and Immunopathology, 2009,128(1-3):178-183.
doi: 10.1016/j.vetimm.2008.10.299
pmid: 19026455
|
[13] |
Harmsen M M, De Haard H J. Properties, production, and applications of camelid single-domain antibody fragments. Applied Microbiology and Biotechnology, 2007,77(1):13-22.
doi: 10.1007/s00253-007-1142-2
pmid: 17704915
|
[14] |
Stijlemans B, Conrath K, Cortez-Retamozo V, et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies - african trypanosomes as paradigm. Journal of Biological Chemistry, 2004,279(2):1256-1261.
doi: 10.1074/jbc.M307341200
pmid: 14527957
|
[15] |
Saerens D, Conrath K, Govaert J, et al. Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. Journal of Molecular Biology, 2008,377(2):478-488.
doi: 10.1016/j.jmb.2008.01.022
pmid: 18262543
|
[16] |
Li M, Fan X D, Liu J, et al. Selection by phage display of nanobodies directed against hypoxia inducible factor-1 alpha (hif-1 alpha). Biotechnology and Applied Biochemistry, 2015,62(6):738-745.
doi: 10.1002/bab.1340
pmid: 25556956
|
[17] |
Dumoulin M, Conrath K, Van Meirhaeghe A, et al. Single-domain antibody fragments with high conformational stability. Protein Science, 2002,11(3):500-515.
doi: 10.1110/ps.34602
pmid: 11847273
|
[18] |
Omidfar K, Daneshpour M. Advances in phage display technology for drug discovery. Expert Opinion on Drug Discovery, 2015,10(6):651-669.
doi: 10.1517/17460441.2015.1037738
pmid: 25910798
|
[19] |
Van Audenhove I, Boucherie C, Pieters L, et al. Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization. FASEB Journal, 2014,28(4):1805-1818.
doi: 10.1096/fj.13-242537
pmid: 24414419
|
[20] |
Van Den Abbeele A, De Clercq S, De Ganck A, et al. A llama-derived gelsolin single-domain antibody blocks gelsolin-g-actin interaction. Cellular and Molecular Life Sciences, 2010,67(9):1519-1535.
doi: 10.1007/s00018-010-0266-1
pmid: 20140750
|
[21] |
Van Audenhove I, Van Impe K, Ruano-Gallego D, et al. Mapping cytoskeletal protein function in cells by means of nanobodies. Cytoskeleton, 2013,70(10):604-622.
doi: 10.1002/cm.21122
pmid: 23818458
|
[22] |
Su C, Nguyen V K, Nei M. Adaptive evolution of variable region genes encoding an unusual type of immunoglobulin in camelids. Molecular Biology and Evolution, 2002,19(3):205-215.
doi: 10.1093/oxfordjournals.molbev.a004073
pmid: 11861879
|
[23] |
Harmsen M M, Ruuls R C, Nijman I J, et al. Llama heavy-chain v regions consist of at least four distinct subfamilies revealing novel sequence features. Molecular Immunology, 2000,37(10):579-590.
doi: 10.1016/s0161-5890(00)00081-x
pmid: 11163394
|
[24] |
Vincke C, Loris R, Saerens D, et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. Journal of Biological Chemistry, 2009,284(5):3273-3284.
doi: 10.1074/jbc.M806889200
pmid: 19010777
|
[25] |
Vaneycken I, Govaert J, Vincke C, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole spect/micro-ct. Journal of Nuclear Medicine, 2010,51(7):1099-1106.
doi: 10.2967/jnumed.109.069823
pmid: 20554727
|
[26] |
Liu W, Song H, Chen Q, et al. Recent advances in the selection and identification of antigen-specific nanobodies. Molecular Immunology, 2018,96:37-47.
doi: 10.1016/j.molimm.2018.02.012
pmid: 29477934
|
[27] |
Salvador J P, Vilaplana L, Marco M P. Nanobody: outstanding features for diagnostic and therapeutic applications. Analytical and Bioanalytical Chemistry, 2019,411(9):1703-1713.
doi: 10.1007/s00216-019-01633-4
pmid: 30734854
|
[28] |
Sheehan J, Marasco W A. Phage and yeast display, 2015,3(1).
|
[29] |
Hussack G, Baral T N, Baardsnes J, et al. A novel affinity tag, abtag, and its application to the affinity screening of single-domain antibodies selected by phage display. Frontiers in Immunology, 2017,8:1406-1406.
doi: 10.3389/fimmu.2017.01406
pmid: 29163485
|
[30] |
Koide A, Tereshko V, Uysal S, et al. Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar kd of a single-domain antibody with a flat paratope. Journal of Molecular Biology, 2007,373(4):941-953.
doi: 10.1016/j.jmb.2007.08.027
pmid: 17888451
|
[31] |
Li M, Fan X, Liu J, et al. Selection by phage display of nanobodies directed against hypoxia inducible factor-1α (hif-1α). Biotechnology and Applied Biochemistry, 2015,62(6):738-45.
doi: 10.1002/bab.1340
pmid: 25556956
|
[32] |
Vanmarsenille C, Del Olmo I D, Elseviers J, et al. Nanobodies targeting conserved epitopes on the major outer membrane protein of campylobacter as potential tools for control of campylobacter colonization. Veterinary Research, 2017,48(1):86.
doi: 10.1186/s13567-017-0491-9
pmid: 29216932
|
[33] |
Keller M A, Stiehm E R. Passive immunity in prevention and treatment of infectious diseases. Clinical Microbiology Reviews, 2000,13(4):602-614.
doi: 10.1128/cmr.13.4.602-614.2000
pmid: 11023960
|
[34] |
Ruano-Gallego D, Yara D A, Di Ianni L, et al. A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic E. Coli to human colonic mucosa. PLoS Pathogens, 2019,15(8):e1008031.
doi: 10.1371/journal.ppat.1008031
pmid: 31465434
|
[35] |
Bakshi S, Garcia R S, Van Der Weken H, et al. Evaluating single-domain antibodies as carriers for targeted vaccine delivery to the small intestinal epithelium. Journal of Controlled Release, 2020,321:416-429.
doi: 10.1016/j.jconrel.2020.01.033
pmid: 31981657
|
[36] |
Van Der Vaart J M, Pant N, Wolvers D, et al. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine, 2006,24(19):4130-4137.
doi: 10.1016/j.vaccine.2006.02.045
pmid: 16616802
|
[37] |
Martin M C, Pant N, Ladero V, et al. Integrative expression system for delivery of antibody fragments by lactobacilli. Applied and Environmental Microbiology, 2011,77(6):2174-2179.
doi: 10.1128/AEM.02690-10
pmid: 21257814
|
[38] |
Tokuhara D, Alvarez B, Mejima M, et al. Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. Journal of Clinical Investigation, 2013,123(9):3829-3838.
doi: 10.1172/JCI70266
pmid: 23925294
|
[39] |
Gray E R, Brookes J C, Caillat C, et al. Unravelling the molecular basis of high affinity nanobodies against hiv p24: in vitro functional, structural, and in silico insights. ACS Infectious Diseases, 2017,3(7):479-491.
doi: 10.1021/acsinfecdis.6b00189
pmid: 28591513
|
[40] |
Zhu M, Gong X, Hu Y, et al. Streptavidin-biotin-based directional double nanobody sandwich elisa for clinical rapid and sensitive detection of influenza h5n1. Journal of Translational Medicine, 2014,12:352.
doi: 10.1186/s12967-014-0352-5
pmid: 25526777
|
[41] |
Rasoulinejad S, Gargari S L M. Aptamer-nanobody based elasa for specific detection of acinetobacter baumannii isolates. Journal of Biotechnology, 2016,231:46-54.
doi: 10.1016/j.jbiotec.2016.05.024
pmid: 27234880
|
[42] |
Deckers N, Saerens D, Kanobana K, et al. Nanobodies, a promising tool for species-specific diagnosis of taenia solium cysticercosis. International Journal for Parasitology, 2009,39(5):625-633.
doi: 10.1016/j.ijpara.2008.10.012
pmid: 19041315
|
[43] |
He Y, Ren Y, Guo B, et al. Development of a specific nanobody and its application in rapid and selective determination of salmonella enteritidis in milk. Food Chemistry, 2020,310:125942.
doi: 10.1016/j.foodchem.2019.125942
pmid: 31830714
|
[44] |
Melli L J, Zylberman V, Hiriart Y, et al. Development and evaluation of a novel vhh-based immunocapture assay for high-sensitivity detection of shiga toxin type 2 (stx2) in stool samples. Journal of Clinical Microbiology, 2020,58(3):e01566-19.
doi: 10.1128/JCM.01566-19
pmid: 31826960
|
[45] |
Cao J, Zhong N, Wang G, et al. Nanobody-based sandwich reporter system for living cell sensing influenza a virus infection. Scientific Reports, 2019,9(1):15899.
doi: 10.1038/s41598-019-52258-7
pmid: 31685871
|
[46] |
Caljon G, Caveliers V, Lahoutte T, et al. Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier. British Journal of Pharmacology, 2012,165(7):2341-2353.
doi: 10.1111/j.1476-5381.2011.01723.x
pmid: 22013955
|
[47] |
Nye S, Whitley R J, Kong M. Viral infection in the development and progression of pediatric acute respiratory distress syndrome. Frontiers in Pediatrics, 2016,4:128.
doi: 10.3389/fped.2016.00128
pmid: 27933286
|
[48] |
Detalle L, Stohr T, Palomo C, et al. Generation and characterization of alx-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrobial Agents and Chemotherapy, 2016,60(1):6-13.
doi: 10.1128/AAC.01802-15
pmid: 26438495
|
[49] |
Mora A L, Detalle L, Gallup J M, et al. Delivery of alx-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. mAbs, 2018,10(5):778-795.
doi: 10.1080/19420862.2018.1470727
pmid: 29733750
|
[50] |
Palomo C, Mas V, Detalle L, et al. Trivalency of a nanobody specific for the human respiratory syncytial virus fusion glycoprotein drastically enhances virus neutralization and impacts escape mutant selection. Antimicrobial Agents and Chemotherapy, 2016,60(11):6498-6509.
doi: 10.1128/AAC.00842-16
pmid: 27550346
|
[51] |
Broadbent L, Parke H G, Ferguson L J, et al. Comparative therapeutic potential of alx-0171 and palivizumab against rsv clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures. Bio Rxiv, 2019: 800326.
|
[52] |
Tillib S V, Ivanova T I, Vasilev L A, et al. Formatted single-domain antibodies can protect mice against infection with influenza virus (h5n2). Antiviral Research, 2013,97(3):245-254.
doi: 10.1016/j.antiviral.2012.12.014
pmid: 23274623
|
[53] |
Tome-Amat J, Ramos I, Amanor F, et al. Influenza a virus utilizes low-affinity, high-avidity interactions with the nuclear import machinery to ensure infection and immune evasion. Journal of Virology, 2019,93(1):e01046.
doi: 10.1128/JVI.01046-18
pmid: 30305352
|
[54] |
Ibanez L I, De Filette M, Hultberg A, et al. Nanobodies with in vitro neutralizing activity protect mice against h5n1 influenza virus infection. The Journal of Infectious Diseases, 2011,203(8):1063-1072.
doi: 10.1093/infdis/jiq168
pmid: 21450996
|
[55] |
Wei G, Meng W, Guo H, et al. Potent neutralization of influenza a virus by a single-domain antibody blocking m2 ion channel protein. PLoS One, 2011,6(12):e28309.
doi: 10.1371/journal.pone.0028309
pmid: 22164266
|
[56] |
Laursen N S, Friesen R H E, Zhu X, et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science, 2018,362(6414):598-602.
doi: 10.1126/science.aaq0620
pmid: 30385580
|
[57] |
Stalin Raj V, Okba N M A, Gutierrez-Alvarez J, et al. Chimeric camel/human heavy-chain antibodies protect against mers-cov infection. Science Advances, 2018, 4(8): eaas9667.
doi: 10.1126/sciadv.aas9667
pmid: 30101189
|
[58] |
Wrapp D, De Vlieger D, Corbett K S, et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell, 2020,181(5):1004-1015.
doi: 10.1016/j.cell.2020.04.031
pmid: 32375025
|
[59] |
Zhao G Y, He L, Sun S H, et al. A novel nanobody targeting Middle East respiratory syndrome coronavirus (mers-cov) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against mers-cov. Journal of Virology, 2018,92(18):e00837.
doi: 10.1128/JVI.00837-18
pmid: 29950421
|
[60] |
Dong J, Huang B, Jia Z, et al. Development of multi-specific humanized llama antibodies blocking sars-cov-2/ace2 interaction with high affinity and avidity. Emerg Microbes Infect, 2020,9(1):1034-1036.
doi: 10.1080/22221751.2020.1768806
pmid: 32403995
|
[61] |
Limited B G. Beroni group r&d team identifies 24 types of nanobodies for rapid detection and treatment of coronavirus (covid-19). [2020-05-08]. https://www.globenewswire.com/news-release/2020/05/08/2030400/0/en/Beroni-Group-R-D-Team-Identifies-24-Types-of-Nanobodies-for-Rapid-Detection-and-Treatment-of-Coronavirus-COVID-19.html.
|
[62] |
Wrapp D, De Vlieger D, Corbett K S, et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell, 2020, 181(5): 1004-1015.e15.
doi: 10.1016/j.cell.2020.04.031
pmid: 32375025
|
[63] |
Huo J, Le Bas A, Ruza R R, et al. Neutralizing nanobodies bind sars-cov-2 spike rbd and block interaction with ace2. Nature Structural & Molecular Biology, 2020.
doi: 10.1038/s41594-020-0504-7
pmid: 32958947
|
[64] |
Walter J D, Hutter C a J, Zimmermann I, et al. Synthetic nanobodies targeting the sars-cov-2 receptor-binding domain. Bio Rxiv, 2020: 2020.04.16.045419.
|
[65] |
Nieto G V, Jara R, Himelreichs J, et al. Fast isolation of sub-nanomolar affinity alpaca nanobody against the spike rbd of sars-cov-2 by combining bacterial display and a simple single-step density gradient selection. Bio Rxiv, 2020: 2020.06.09.137935.
|
[66] |
Li T, Cai H, Yao H, et al. Potent synthetic nanobodies against sars-cov-2 and molecular basis for neutralization. Bio Rxiv, 2020: 2020.06.09.143438.
|
[67] |
Custódio T F, Das H, Sheward D J, et al. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize sars-cov-2. Bio Rxiv, 2020: 2020.06.23.165415.
|
[68] |
Hanke L, Vidakovics M, Sheward D, et al. An alpaca nanobody neutralizes sars-cov-2 by blocking receptor interaction. 2020.
|
[69] |
Matz J, Kessler P, Bouchet J, et al. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved cd4 and coreceptor binding sites of hiv-1 gp120. Journal of Virology, 2013,87(2):1137-1149.
doi: 10.1128/JVI.00461-12
pmid: 23152508
|
[70] |
Koch K, Kalusche S, Torres J L, et al. Selection of nanobodies with broad neutralizing potential against primary hiv-1 strains using soluble subtype c gp140 envelope trimers. Scientific Reports, 2017,7(1):8390.
doi: 10.1038/s41598-017-08273-7
pmid: 28827559
|
[71] |
Weiss R A, Verrips C T. Nanobodies that neutralize hiv. Vaccines, 2019,7(3):77.
doi: 10.3390/vaccines7030077
|
[72] |
Van Hout A, Klarenbeek A, Bobkov V, et al. Cxcr4-targeting nanobodies differentially inhibit cxcr4 function and hiv entry. Biochemical Pharmacology, 2018,158:402-412.
doi: 10.1016/j.bcp.2018.10.015
pmid: 30342024
|
[73] |
Boons E, Li G, Vanstreels E, et al. A stably expressed llama single-domain intrabody targeting rev displays broad-spectrum anti-hiv activity. Antiviral Research, 2014,112:91-102.
doi: 10.1016/j.antiviral.2014.10.007
pmid: 25453342
|
[74] |
Lutje Hulsik D, Liu Y Y, Strokappe N M, et al. A gp41 mper-specific llama vhh requires a hydrophobic cdr3 for neutralization but not for antigen recognition. PLoS Pathogens, 2013,9(3):e1003202.
doi: 10.1371/journal.ppat.1003202
pmid: 23505368
|
[75] |
Daka A, Peer D. Rnai-based nanomedicines for targeted personalized therapy. Advanced Drug Delivery Reviews, 2012,64(13):1508-1521.
doi: 10.1016/j.addr.2012.08.014
pmid: 22975009
|
[76] |
Cunha-Santos C, Perdigao P R L, Martin F, et al. Inhibition of hiv replication through sirna carried by cxcr4-targeted chimeric nanobody. Cellular and Molecular Life Sciences, 2019.
doi: 10.1007/s00018-020-03678-6
pmid: 33078208
|
[77] |
Li S F, Zhang W, Jiang K P, et al. Nanobody against the e7 oncoprotein of human papillomavirus 16. Molecular Immunology, 2019,109:12-19.
doi: 10.1016/j.molimm.2019.02.022
pmid: 30849663
|
[78] |
Woodham A W, Cheloha R W, Ling J J, et al. Nanobody-antigen conjugates elicit hpv-specific antitumor immune responses. Cancer Immunology Research, 2018,6(7):870-880.
doi: 10.1158/2326-6066.CIR-17-0661
pmid: 29792298
|
[79] |
De Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology, 2012,13(6):607-615.
doi: 10.1016/S1470-2045(12)70137-7
pmid: 22575588
|
[80] |
Walsh R, Nuttall S, Revill P, et al. Targeting the hepatitis b virus precore antigen with a novel ignar single variable domain intrabody. Virology, 2011,411(1):132-141.
doi: 10.1016/j.virol.2010.12.034
pmid: 21239030
|
[81] |
Tarr A W, Lafaye P, Meredith L, et al. An alpaca nanobody inhibits hepatitis c virus entry and cell-to-cell transmission. Hepatology, 2013,58(3):932-939.
doi: 10.1002/hep.26430
pmid: 23553604
|
[82] |
Koromyslova A D, Hausman G S. Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization. Biophysical Journal, 2018,114(3):219a-219a.
|
[83] |
Geoghegan E M, Zhang H, Desai P J, et al. Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein d of herpes simplex virus 2. Antimicrobial Agents and Chemotherapy, 2015,59(1):527-535.
doi: 10.1128/AAC.03818-14
pmid: 25385102
|
[84] |
Conrath K E, Lauwereys M, Galleni M, et al. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrobial Agents and Chemotherapy, 2001,45(10):2807-2812.
doi: 10.1128/AAC.45.10.2807-2812.2001
pmid: 11557473
|
[85] |
Barta M L, Shearer J P, Arizmendi O, et al. Single-domain antibodies pinpoint potential targets within shigella invasion plasmid antigen d of the needle tip complex for inhibition of type iii secretion. Journal of Biological Chemistry, 2017,292(40):16677-16687.
doi: 10.1074/jbc.M117.802231
pmid: 28842484
|
[86] |
King M T, Huh I, Shenai A, et al. Structural basis of vhh-mediated neutralization of the food-borne pathogen listeria monocytogenes. Journal of Biological Chemistry, 2018,293(35):13626-13635.
doi: 10.1074/jbc.RA118.003888
pmid: 29976754
|
[87] |
Ebrahimizadeh W, Mousavi Gargari S, Rajabibazl M, et al. Isolation and characterization of protective anti-lps nanobody against v. Cholerae o1 recognizing inaba and ogawa serotypes. Applied Microbiology and Biotechnology, 2013,97(10):4457-4466.
doi: 10.1007/s00253-012-4518-x
pmid: 23135228
|
[88] |
Baral T N, Magez S, Stijlemans B, et al. Experimental therapy of african trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nature Medicine, 2006,12(5):580-584.
doi: 10.1038/nm1395
pmid: 16604085
|
[89] |
Arias J L Unciti-Broceta J D Maceira J, et al. Nanobody conjugated plga nanoparticles for active targeting of african trypanosomiasis. Journal of Controlled Release, 2015,197:190-198.
doi: 10.1016/j.jconrel.2014.11.002
pmid: 25445702
|
[90] |
Unciti-Broceta J D, Arias J L, Maceira J, et al. Specific cell targeting therapy bypasses drug resistance mechanisms in african trypanosomiasis. PLoS Pathogens, 2015,11(6):e1004942.
doi: 10.1371/journal.ppat.1004942
pmid: 26110623
|
[91] |
Wu Y, Jiang S, Ying T. Single-domain antibodies as therapeutics against human viral diseases. Frontiers in Immunology, 2017,8:1802.
doi: 10.3389/fimmu.2017.01802
pmid: 29326699
|
[92] |
Keyaerts M, Xavier C, Heemskerk J, et al. Phase i study of 68ga-her2-nanobody for pet/ct assessment of her2 expression in breast carcinoma. Journal of Nuclear Medicine, 2016,57(1):27-33.
doi: 10.2967/jnumed.115.162024
pmid: 26449837
|
[93] |
Lemke J, Von Karstedt S, Zinngrebe J, et al. Getting trail back on track for cancer therapy. Cell Death and Differentiation, 2014,21(9):1350-1364.
doi: 10.1038/cdd.2014.81
pmid: 24948009
|
[94] |
Wu Y, Li C, Xia S, et al. Identification of human single-domain antibodies against sars-cov-2. Cell Host & Microbe, 2020, 27(6): 891-898.e5.
doi: 10.1016/j.chom.2020.04.023
pmid: 32413276
|
[95] |
Dolk E, Van Der Vaart M, Lutje Hulsik D, et al. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Applied and Environmental Microbiology, 2005,71(1):442-450.
doi: 10.1128/AEM.71.1.442-450.2005
pmid: 15640220
|
[96] |
2018新型抗体药物论坛. 传遍了朋友圈的羊驼-纳米抗体平台究竟是什么.[ 2018-10-26]. http://meeting.bioon.com/2018NA/news-detail/c8098462ec0323e6.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|